Pubblicazioni

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII). a multicentre, open-label, phase 3b, randomised controlled trial

2019 - THE LANCET DIABETES & ENDOCRINOLOGY
Aroda, Vr; González-Galvez, G; Grøn, R; Halladin, N; Haluzík, M; Jermendy, G; Kok, A; Őrsy, P; Sabbah, M; Sesti, G; Silver, R.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma